

NICE Technology Appraisals About Medicines: Formulary Adherence

Technology appraisal (TA) are hyperlinks to full guidance	Titles	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE	
				Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
2006-07					
Leukaemia (lymphocytic) - fludarabine (TA119)		28/02/2007	Fludarabine – monotherapy not recommended as initial treatment for chronic lymphocytic leukaemia.	Yes	
Breast cancer - gemcitabine (TA116)		31/01/2007	Gemcitabine with paclitaxel – a recommended option for metastatic breast cancer only when docetaxel monotherapy or docetaxel plus capecitabine are also appropriate.	No	This medicine is not applicable to C&W
Colorectal cancer (metastatic) - bevacizumab and cetuximab (TA118) (partially updated by TA242)		31/01/2007	Bevacizumab with 5-fluorouracil plus folinic acid, with or without irinotecan – not recommended first line. Cetuximab with irinotecan – not recommended if previous treatment included irinotecan.	No	This medicine is not applicable to C&W
Hyperparathyroidism - cinacalcet (TA117)		31/01/2007	Cinacalcet – recommended for people on dialysis with hyperparathyroidism only if unresponsive to other treatments or if parathyroidectomy unsuitable.	No	This medicine is not applicable to C&W
Drug misuse - methadone and buprenorphine (TA114)		31/01/2007	Methadone, buprenorphine (oral) – recommended options for opioid dependence as part of a support programme, with supervised administration for at least the first 3 months.	No	This medicine is not applicable to C&W
Drug misuse - naltrexone (TA115)		31/01/2007	Naltrexone – a recommended option for opioid dependent people who have stopped opioids, but are highly motivated to stay free from the drugs in an abstinence programme.	No	This medicine is not applicable to C&W
Breast cancer (early) - hormonal treatments (TA112)		30/11/2006	Anastrozole, exemestane, letrozole – recommended adjuvant options after surgery for early oestrogen-receptor-positive breast cancer post-menopause.	No	This medicine is not applicable to C&W
Breast cancer (early) - paclitaxel (TA108)		30/09/2006	Paclitaxel – not recommended for the adjuvant treatment of women with early node-positive breast cancer. Updated by CG80	No	This medicine is not applicable to C&W
Breast cancer (early) - docetaxel (TA109)		30/09/2006	Docetaxel – a recommended adjuvant option with doxorubicin and cyclophosphamide for early node-positive breast cancer. Updated by CG80	No	This medicine is not applicable to C&W
Breast cancer (early) - trastuzumab (TA107)		31/08/2006	Trastuzumab – a recommended option for early-stage HER2-positive breast cancer after surgery, chemotherapy, and radiotherapy if applicable. Updated by CG80 .	No	This medicine is not applicable to C&W

Hepatitis C - peginterferon alfa and ribavirin (TA106) Extension of TA75 and partially updated by TA200	31/08/2006	Peginterferon alfa and ribavirin – a recommended option for mild chronic hepatitis C. If ribavirin is unsuitable, use peginterferon monotherapy. No recommendation on use in the under 18s, or after liver transplant, due to lack of evidence.	Yes	
Psoriasis - efalizumab and etanercept (TA103)	31/07/2006	Etanercept – a recommended option for severe plaque psoriasis if other treatments are unsuitable, unsuccessful or not tolerated. Efalizumab – drug withdrawn.	Yes	
Prostate cancer (hormone-refractory) - docetaxel (TA101)	30/06/2006	Docetaxel – a recommended option for hormone-refractory metastatic prostate cancer with Karnofsky score 60% or more. Not recommended if the disease recurs after a first course.	Yes	
Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)	30/04/2006	Recommended options after surgery for stage III (Dukes' C) colon cancer: Capecitabine – as monotherapy. Oxaliplatin – with 5-fluorouracil and folinic acid.	No	This medicine is not applicable to C&W
Renal transplantation - immunosuppressive regimens for children and adolescents (TA99)	30/04/2006	Basiliximab, daclizumab – consider for induction therapy with combinations that include ciclosporin. Tacrolimus – an alternative to ciclosporin for initial therapy or maintenance. Mycophenolate mofetil – Only consider when intolerant of calcineurin inhibitors (ciclosporin-like drugs). Mycophenolate sodium – not recommended. Sirolimus – not recommended unless intolerant of calcineurin inhibitors.	No	This medicine is not applicable to C&W